TY - JOUR
T1 - Assessing symptom burden using the M. D. Anderson Symptom Inventory in patients with chemotherapy-induced anemia
T2 - Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-α at a dose of 200 μg every 2 weeks
AU - Gabrilove, Janice L.
AU - Perez, Edith A.
AU - Tomita, Dianne K.
AU - Rossi, Greg
AU - Cleeland, Charles S.
PY - 2007/10/1
Y1 - 2007/10/1
N2 - BACKGROUND. Patients with cancer who are receiving chemotherapy often experience chemotherapy-induced anemia (CIA), which is associated with symptoms that reduce quality of life. The M. D. Anderson Symptom Inventory (MDASI) is a brief, self-rating assessment scale that measures the severity of core symptoms and symptom interference with function. The current study used the MDASI to prospectively assess the correlation between hemoglobin and self-perceived cancer-related symptoms in a large patient population with CIA who were receiving darbepoetin-α at a dose of 200 μg every 2 weeks. METHODS. Eligible patients enrolled in this multicenter, open-label study were age ≥18 years, had a nonmyeloid malignancy, were receiving multicycle chemotherapy, and were anemic (hemoglobin ≤11 g/dL). Hemoglobin was measured every 2 weeks; the MDASI was administered weekly. For hemoglobin-based end-points, patients were stratified by baseline hemoglobin (<10 g/dL or ≥10 g/dL). RESULTS. Of 2422 enrolled patients, 2401 received ≥1 dose of darbepoetin-α. Eighty percent of patients (95% confidence limit, 78-82 patients) achieved target hemoglobin levels (≥11 g/dL) during the study. Patients with a baseline hemoglobin <10 g/dL had a greater increase in hemoglobin, took longer to achieve the target hemoglobin, and received more red blood cell transfusions than patients with a baseline hemoglobin ≥10 g/dL. The percentage of patients with moderate to severe MDASI scores (≥5 points) for fatigue, distress, loss of appetite, disturbed sleep, and interference with function was reduced during the study. Improvement in symptom burden was associated with an increase in hemoglobin concentration. CONCLUSIONS. Treatment with darbepoetin-α at a dose of 200 μg every 2 weeks is associated with improvement in symptom burden as measured by the MDASI, a simple tool that may improve symptom management for cancer patients with CIA.
AB - BACKGROUND. Patients with cancer who are receiving chemotherapy often experience chemotherapy-induced anemia (CIA), which is associated with symptoms that reduce quality of life. The M. D. Anderson Symptom Inventory (MDASI) is a brief, self-rating assessment scale that measures the severity of core symptoms and symptom interference with function. The current study used the MDASI to prospectively assess the correlation between hemoglobin and self-perceived cancer-related symptoms in a large patient population with CIA who were receiving darbepoetin-α at a dose of 200 μg every 2 weeks. METHODS. Eligible patients enrolled in this multicenter, open-label study were age ≥18 years, had a nonmyeloid malignancy, were receiving multicycle chemotherapy, and were anemic (hemoglobin ≤11 g/dL). Hemoglobin was measured every 2 weeks; the MDASI was administered weekly. For hemoglobin-based end-points, patients were stratified by baseline hemoglobin (<10 g/dL or ≥10 g/dL). RESULTS. Of 2422 enrolled patients, 2401 received ≥1 dose of darbepoetin-α. Eighty percent of patients (95% confidence limit, 78-82 patients) achieved target hemoglobin levels (≥11 g/dL) during the study. Patients with a baseline hemoglobin <10 g/dL had a greater increase in hemoglobin, took longer to achieve the target hemoglobin, and received more red blood cell transfusions than patients with a baseline hemoglobin ≥10 g/dL. The percentage of patients with moderate to severe MDASI scores (≥5 points) for fatigue, distress, loss of appetite, disturbed sleep, and interference with function was reduced during the study. Improvement in symptom burden was associated with an increase in hemoglobin concentration. CONCLUSIONS. Treatment with darbepoetin-α at a dose of 200 μg every 2 weeks is associated with improvement in symptom burden as measured by the MDASI, a simple tool that may improve symptom management for cancer patients with CIA.
KW - Anemia
KW - Chemotherapy
KW - Darbepoetin-α
KW - Hemoglobin
KW - M. D. Anderson Symptom Inventory (MDASI)
KW - Quality of life
KW - Symptom burden
KW - Transfusions
UR - http://www.scopus.com/inward/record.url?scp=34648833614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34648833614&partnerID=8YFLogxK
U2 - 10.1002/cncr.22943
DO - 10.1002/cncr.22943
M3 - Article
C2 - 17694552
AN - SCOPUS:34648833614
SN - 0008-543X
VL - 110
SP - 1629
EP - 1640
JO - Cancer
JF - Cancer
IS - 7
ER -